A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.

Study Overview

• Status: Recruiting
• Conditions: Malignant Solid Tumor
• Intervention / Treatment: Drug: ASKB589 Injection

• Study Type: Interventional
• Enrollment (Anticipated): 214
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Yurong Wang; Phone Number: 025-8509062; Email: wangyurong@ask-pharm.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100089
      • Recruiting
      • Beijing Cancer Hospital
      • Contact: Lin Shen; Email: doctorshenlin@sina.cn
  • Shandong
    • Linyi, Shandong, China, 276000
      • Recruiting
      • LinYi Cancer Hospital
      • Contact: Hua Jian Shi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. According to RECIST 1.1 criteria, all patients must have at least one measurable lesion, and the tumor lesions must be accurately measured in at least one dimension, and lesions previously treated with radiotherapy or local therapy are only evaluated as non-target lesions. Bone metastatic lesions are not considered as measurable lesions;
2. ECOG performance status (PS) 0-1;
3. The results of the laboratory tests must meet all the following criteria:

（1）Haemoglobin≥9 g/dL；platelet count≥ 100 × 109/L；absolute neutrophil count≥ 1.5 × 109/L；

（2）Albumin≥ 3.0g/dL；total bilirubin ≤ 1.5 times the upper limit of normal (ULN)；aspartate transaminase and alanine aminotransferase≤ 2.5 times ULN if no demonstrable liver metastases ( ≤5 times ULN in the presence of liver metastases);

（3）Creatinine clearance≥ 50ml/min；

（4）Prothrombin time, international normalized ratio, and activated partial thromboplastin time≤1.5×ULN (except for patients receiving anticoagulant therapy)

4.Life expectancy of at least 3 months;

5.Patients who are supposed to be enrolled into the monotherapy dose escalation study must meet all the following criteria:

1. Patients of either gender, aged from 18 years old to 70;
2. Patients with histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic malignant solid tumor, for whom have no standard therapy or have no access to standard therapy for various reasons.

6.Patients who are supposed to be enrolled into the monotherapy dose expansion study must meet all the following criteria:

1. Patients of either gender, aged from 18 years old to 75；
2. Patients with histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer, for whom have no standard therapy or have no access to standard therapy for various reasons, and that tumor tissue samples are CLDN18.2 positive detected by central laboratory (medium-high expression)；
3. Other tumor types with good potential benefits will be included according to the results of the clinical results of same target products (CLDN18.2-positive tumors).

7.Patients who are supposed to be enrolled into the dose escalation of ASKB589 combined with chemotherapy should meet all the following criteria:

1. Patients of either gender, aged from 18 years old to 70.
2. Patients with gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer who are tolerant to CAPOX, GEM+Nab-P chemotherapy.
3. Patients with gastric cancer, gastroesophageal junction adenocarcinoma who are intolerant to anti-human epidermal growth factor receptor 2 (anti-HER2) drug therapy.
4. Other tumor types with good potential benefits will be included according to the results of mono-therapy dose expansion and the clinical results of same target products.

8.Patients who are supposed to be enrolled into the dose expansion of ASKB589 combined with chemotherapy should meet all the following criteria:

1. Patients of either gender, aged from 18 years old to 75.
2. Patients with gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer who are tolerant to CAPOX, GEM+Nab-P chemotherapy, and that tumor tissue samples are CLDN18.2 positive detected by central laboratory (medium-high expression).
3. Patients with gastric cancer, gastroesophageal junction adenocarcinoma that who are intolerant to anti-HER2 drug therapy.
4. Other tumor types with good potential benefits will be included according to the results of this study and the clinical results of same target products.

Exclusion Criteria:

1. Patients have a history of severe allergic reactions to monoclonal antibodies or are intolerance to monoclonal antibodies, or those who are allergic to experimental drug and any component of the drug.
2. Patients have received a treatment of whole blood or blood component transfusion or various growth factor treatments within 14 days prior to enrollment.
3. Patients have received anti-tumor therapy within 14 days prior to enrollment，including but not limited to radiotherapy, chemotherapy, targeted therapy, treatment with herbal medications or other treatments that have known antitumor activity . Patients who have undergone palliative radiotherapy for bone metastases and whose acute toxicity has returned to normal can be selected;
4. Patients have received systemic immunosuppressive therapy（such as systemic corticosteroids）within 14 days prior to enrollment. However, patients using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30mg per day of hydrocortisone or 10mg per day of prednisone) are allowed；patients are allowed to receive a single dose of systemic corticosteroids treatment；
5. Patients have participated in other clinical trials within 28 days prior to enrollment; patients who have participated monoclonal antibody clinical trials within 2 months prior to sign written informed consent form also cannot participate in this trial；
6. Patients have received major surgical operation within 28 days prior to enrollment or schedule to perform major surgery during the period of this clinical trial;
7. Patients have gastrointestinal diseases such as gastrinoma, duodenitis, gastric ulcer, duodenal ulcer, pancreatitis or upper gastrointestinal hemorrhage, caused by nonmalignant tumor (gastric cancer, gastroesophageal junction adenocarcinoma and pancreatic cancer)；
8. Known to have irritable bowel syndrome, ulcerative colitis, Crohn's disease, gastric outlet obstruction, etc., or any other causes that can cause long-term chronic nausea,persistent repeated vomiting or diarrhea, and uncontrolled or severe gastrointestinal bleeding;
9. Have a history of diagnosed neurological or mental disorders, including epilepsy or dementia;
10. Patients with any other malignant tumors within the past 5 years, cured cervical carcinoma in situ, basal cell, or squamous cell skin cancer are not included.
11. Known active central nervous system (CNS) metastasis or suspected cancerous meningitis;
12. There are moderate to large amounts of abdominal and pleural fluid. However, a small number of asymptomatic and pleural effusion patients who do not need treatment are allowed to be included;
13. Patients currently suffering from diseases that affect intravenous injection and venous blood sampling;
14. Patients suffering from major cardiovascular diseases, including:

（1）Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months before the first drug treatment；

（2）History of clinically significant ventricular arrhythmia (such as sustained ventricular tachycardia, ventricular fibrillation or torsade de pointes)；

（3）Patients have an abnormality in the 12-lead electrocardiogram (ECG) including a Fridericia's corrected QT interval (QTcF) greater than 450 milliseconds (ms) (males) or greater than 470 ms (females).

（4）History or family history of congenital long QT syndrome；

（5）Cardiac arrhythmias requiring anti-arrhythmic drug therapy (patients suffering from atrial fibrillation >1 month before the first administration of drug can be selected according to the condition of patients);

（6）Left ventricular ejection fraction <50%；

15.Pregnant or lactating women; or women of childbearing age who have a positive blood pregnancy test during screening period; or women of childbearing age and their spouses who are unwilling to take effective contraceptive measures during the period of this clinical trial and within 6 months after the end of the clinical trial;

16.Patients who are not meet the inclusion criteria based on the judgment of investigator；

17.Patients included in dose-escalation and expansion study of combined chemotherapy should also exclude:

1. Patients with gastric cancer, gastroesophageal junction adenocarcinoma who are allergic, intolerant or contraindicated to any other components of capecitabine and oxaliplatin.
2. Patients with pancreatic cancer who are allergic, intolerant or contraindicated any components of gemcitabine and albumin bound paclitaxel for injection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ASKB589 Injection; Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.	Drug: ASKB589 Injection; ASKB589 Injection with dose escalation stage of 0.3mg/kg up to10mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events as assessed by CTCAE v5.0	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be presented.	up to 21 days following last dose
The recommended dose	The recommended dose will be determined during the dose escalation and dose expansion stage of the study.	from date of treatment start until data cut-off, up to 2 years
Number of participants with serious adverse events (SAE) as assessed by CTCAE v5.0	An SAE is defined as any untoward medical occurrence that, at any dose: a.) Results in death; b.) Is life-threatening; c.) Requires inpatient hospitalization or prolongation of existing hospitalization; d.) Results in persistent or significant disability/incapacity; e.) Is a congenital anomaly/birth defect; f.) Other important medical events; h.) Is a new cancer (that is not a condition of the study) or i.) Is associated with an overdose. The number of participants who experience an SAE will be presented.	up to 21 days following last dose
The incidence and case number of DLT (Dose Limiting Toxicity) during observation period	DLT is short for Dose Limiting Toxicity，dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.	up to 21 days following first dose
Maximum Tolerated Dose (MTD）	The MTD was defined as the highest dose of ASKB589 not causing DLT in more than 33% of patients in the first treatment cycle.	up to 21days following first dose
Objective response rate	Evaluation of objective response rate assessed by response evaluation criteria in solid tumors version 1.1(RECIST 1.1)	from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics:maximum Plasma Concentration [Cmax]	Serum samples will be collected for Cmax analysis.	Up to 21 days after injection
Pharmacokinetics:time to maximum observed plasma concentration (Tmax)	Serum samples will be collected for Tmax analysis.	Up to 21 days after injection
Pharmacokinetics:terminal elimination half life (T1/2)	Serum samples will be collected for T1/2 analysis.	Up to 21 days after injection
Pharmacokinetics:apparent volume of distribution (Vz/F)	Serum samples will be collected for Vz/F analysis.	Up to 21 days after injection
Pharmacokinetics:Area Under Curve (AUC)	Serum samples will be collected for AUC analysis.	Up to 21 days after injection
Pharmacokinetics: Mean ResidenceTime（MRT）	Serum samples will be collected for MRT analysis.	Up to 21 days after injection
Pharmacokinetics: plasma clearance rate (CL)	Serum samples will be collected for CL analysis.	Up to 21 days after injection
Pharmacokinetics: steady-state peak concentration (Css_max)	Serum samples will be collected for Css_max analysis.	Up to 21 days after injection
Pharmacokinetics: time to steady-state peak concentration (Tss_max)	Serum samples will be collected for Tss_max analysis.	Up to 21 days after injection
Pharmacokinetics: minimum value of steady plasma drug concentration（Css_min）	Serum samples will be collected for Css max analysis.	Up to 21 days after injection
Evaluation of immunogenicity	Incidence of anti-drug antibodies (ADA)	from date of treatment start until data cut-off, up to 2 years
Objective response rate（ORR）	Evaluation of objective response rate assessed by RECIST 1.1	from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
Duration of Response（DOR）	Duration of response assessed by RECIST 1.1	from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
Pharmacokinetics:elimination rate constant（Kel）	Serum samples will be collected for Kel analysis.	Up to 21 days after injection
disease control rate（DCR）	Evaluation of Disease control rate assessed by RECIST 1.1	from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
Progression free survival（PFS）	Progression of tumor will be measured by RECIST v1.1	from date of treatment start until the date of disease progression or until death due to any causes, up to 2 years.
Overall survival（OS）	defined as the time from the date of treatment start until date of death due to any cause	from the date of treatment start until the documented date of death from any cause，up to 2 years.

Collaborators and Investigators

• Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
• Collaborators: Jiangsu Aosaikang Biomedicine Co. LTD.

Study record dates

Study Major Dates

• Study Start (Actual): January 28, 2021
• Primary Completion (Anticipated): December 31, 2024
• Study Completion (Anticipated): December 31, 2025

Study Registration Dates

• First Submitted: November 5, 2020
• First Submitted That Met QC Criteria: November 11, 2020
• First Posted (Actual): November 17, 2020

Study Record Updates

• Last Update Posted (Estimate): February 16, 2023
• Last Update Submitted That Met QC Criteria: February 15, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: ASK-LC-B589-I/II

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No